NEW YORK (GenomeWeb) – CareDx reported today that its first quarter revenues grew 76 percent year over year, amid growing sales of its AlloMap heart transplant test.

For the three months ended March 31, CareDx's revenues rose to $11.6 million from $6.6 million in the same period last year, topping analysts' consensus revenues estimate of $11.3 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.